Real-World check: does ribociclib deliver for early breast cancer patients?
NCT ID NCT07243002
First seen Nov 21, 2025 · Last updated May 13, 2026 · Updated 18 times
Summary
This study watches 3,000 people with hormone-positive, HER2-negative stage II or III breast cancer who are already taking ribociclib or abemaciclib with hormone therapy. Researchers will look at medical records and ask patients about their quality of life, side effects, and how well they stick to the medication. The goal is to see how these drugs work outside of clinical trials, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGLondon, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.